Immunicum AB (DE:1YG0)

FRANKFURT:1YG0

1YG0

Immunicum AB

RESEARCH TOOLSreports

Immunicum AB (1YG0) Price & Analysis

1 Followers

1YG0 Stock Chart & Stats

€0.49

-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.49

-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.35 - €0.87

Previous CloseN/A

Volume0.00

Average Volume (3M)16.00

Market Cap

€28.92M

Enterprise Value€233.33M

Total Cash (Recent Filing)€74.13M

Total Debt (Recent Filing)€18.67M

Price to Earnings (P/E)―

Beta0.31

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.90

Shares Outstanding62,584,580

10 Day Avg. Volume50

30 Day Avg. Volume16

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)0.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.15

Revenue Forecast (FY)€230.28K

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetA low debt-to-equity ratio (~3% TTM) materially reduces solvency and interest burden risk for a clinical-stage biotech. This structural strength improves runway flexibility, supports continued R&D spending, and lowers immediate refinancing pressure compared with highly leveraged peers.

Improving Cash Burn TrajectoryReduced cash burn versus 2023 indicates the company is beginning to slow cash outflows, a durable operational improvement. If sustained, this trend lengthens financing runway, reduces dilution needs over time, and increases the odds of advancing clinical programs without urgent capital raises.

Focused Clinical-stage R&D PipelineA clear focus on immune-oncology and clinical-stage cell therapies provides strategic clarity and scientific specialization. This durable positioning attracts targeted partners, grant funding, and skilled talent, and concentrates resources on advancing a small number of programs toward value-accretive inflection points.

Bears Say

Revenue Collapsed To Near ZeroNear-zero recurring revenue means the business lacks commercial cashflow to fund operations. Over the medium term this forces reliance on external financing or partnerships, increases execution risk for clinical programs, and makes sustained investment in development contingent on non-operating capital.

Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow is a structural vulnerability for a clinical-stage biotech: it necessitates recurring capital raises, risks shareholder dilution, and can delay or constrain trials. Without a durable shift to break-even, program progression depends on external funding timing.

Large Ongoing Losses And Negative ReturnsSustained large losses and materially negative ROE indicate value erosion and weak profitability economics. Over months this limits ability to self-finance, undermines investor confidence for long-term funding, and raises the bar for any partner or acquirer to justify investment absent clear clinical de-risking.

1YG0 FAQ

What was Immunicum AB’s price range in the past 12 months?

Immunicum AB lowest stock price was €0.35 and its highest was €0.87 in the past 12 months.

What is Immunicum AB’s market cap?

Immunicum AB’s market cap is €28.92M.

When is Immunicum AB’s upcoming earnings report date?

Immunicum AB’s upcoming earnings report date is Aug 20, 2026 which is in 69 days.

How were Immunicum AB’s earnings last quarter?

Immunicum AB released its earnings results on May 08, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.031.

Is Immunicum AB overvalued?

According to Wall Street analysts Immunicum AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunicum AB pay dividends?

Immunicum AB does not currently pay dividends.

What is Immunicum AB’s EPS estimate?

Immunicum AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunicum AB have?

Immunicum AB has 62,584,580 shares outstanding.

What happened to Immunicum AB’s price movement after its last earnings report?

Immunicum AB reported an EPS of -€0.031 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.226%.

Which hedge fund is a major shareholder of Immunicum AB?

Currently, no hedge funds are holding shares in DE:1YG0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immunicum AB

Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.